Physician profile
Mary Ellen Ryan
NPI 1003108747
$2,551.86
in general payments reported to CMS, 2019-2025
16 companies · $621 in 2025
The $621 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $380 · 2022: $260 · 2023: $809 · 2024: $482 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,911.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $249.98 | 2024-2025 | |
| Neurelis, INC. | $246.18 | 2023-2024 | Valtoco |
| Novo Nordisk INC | $241.33 | 2022 | |
| Biogen, INC. | $193.22 | 2023 | |
| Ucb, INC. | $188.76 | 2023-2024 | Fintepla |
| Aquestive Therapeutics, INC. | $183.21 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $164.60 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $157.98 | 2025 | Auvelity |
| Genentech USA, INC. | $149.50 | 2025 | Xolair |
| Jazz Pharmaceuticals INC. | $125.01 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $123.93 | 2025 | Entyvio |
| Glaxosmithkline, LLC. | $122.91 | 2023 | Arexvy |
| Biohaven Pharmaceuticals, INC. | $115.38 | 2021 | |
| Gilead Sciences, INC. | $100.00 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $64.87 | 2025 | Fasenra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ellen Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.